Dear editor,

The pandemics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have become a world health crisis that cause significant loss of life. The dysregulated host response to SARS-CoV-2 appears to be associated with the severity and poor outcomes of coronavirus disease 2019 (COVID-19) patients \[[@CR1]\], hinting the critical involvement of SARS-CoV-2-induced sepsis based on Sepsis 3.0 definition \[[@CR2]--[@CR4]\]. The development of sepsis accounts for one of the leading causes of death in patients admitted to intensive care units (ICU), but evidences on viral sepsis remain scarce in current clinical practices, let alone its differences with bacterial sepsis. Given the pandemics of SARS-CoV-2 infection \[[@CR5]\], the differences between viral and bacterial sepsis are indeed of great significance to deepen the understanding of the pathogenesis of sepsis.

In this study, we obtained the clinical data from two cohorts up to May 13, 2020, including 41 critically ill COVID-19 patients from the Third People's Hospital of Shenzhen and 194 non-COVID-19 patients admitted to ICU of the Second People's Hospital of Shenzhen, China. Demographic characteristics, comorbidities, and laboratory findings on ICU admission and clinical outcomes were collected. Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were calculated within the first 24 h since ICU admission. The bacterial and viral sepsis were identified by blood culture and metagenomic next-generation sequencing.

Twenty-one patients with SARS-CoV-2-induced sepsis and 46 patients with bacterial sepsis were finally recruited (Additional file [2](#MOESM2){ref-type="media"}). The median age was 64.0 years (IQR, 60.5--68.0) and 65.5 years (IQR, 49.3--77.3) for patients of SARS-CoV-2-induced sepsis and bacterial sepsis, respectively (Additional file [1](#MOESM1){ref-type="media"}). The prognostic scoring system, including SOFA \[6.0 (IQR, 4.0--9.0) vs. 4.0 (IQR, 3.5--5.0), *P* = 0.01\] and APACHE II \[17.0 (IQR, 13.0--20.3) vs. 8.0 (IQR, 6.5--9.5), *P* \< 0.001\] were consistently higher among patients with bacterial sepsis than those with SARS-CoV-2-induced sepsis. Meanwhile, ICU mortality rates were significantly higher in patients with bacterial sepsis than those with viral sepsis \[34.8% (16/46) vs. 4.8% (1/21), *P* = 0.013\].

As presented in Table [1](#Tab1){ref-type="table"}, absolute counts of T lymphocytes, cytotoxic T lymphocytes (Tc), and helper T lymphocytes (Th) were significantly lower among patients with SARS-CoV-2-induced sepsis at ICU admission, while elevated inflammation-related parameters, C-reactive protein (CRP) as an example, were observed in this cohort compared to patients with bacterial sepsis. In addition, obvious differences in organ functional parameters were noted between the two cohorts, including significantly increased levels of creatine kinase-MB and NT-pro BNP, and decreased albumin level in patients with developed bacterial sepsis. Table 1Comparison of laboratory findings between SARS-CoV-2- and bacteria-induced septic patients admitted to ICUItemNormal rangeTotal (*n* = 67)SARS-CoV-2-induced sepsis (*n* = 21)Bacteria-induced sepsis (*n* = 46)*P***Blood routine test** White blood cell counts (× 10^9^/L)3.5--9.59.6 (6.1--15.9)7.0 (4.7--10.9)11.7 (6.6--17.3)0.007 Neutrophil counts (× 10^9^/L)1.8--6.39.0 (4.3--13.9)5.8 (3.6--8.9)11.1 (5.5--15.3)0.003 Lymphocyte counts (× 10^9^/L)1.1--3.20.7 (0.5--1.0)0.6 (0.6--0.8)0.7 (0.5--1.0)0.68 Neutrophil to lymphocyte ratioNA11.0 (4.8--21.5)9.5 (4.5--13.1)12.2 (6.0--24.6)0.094 Monocyte counts (× 10^9^/L)0.1--0.60.4 (0.2--0.8)0.4 (0.2--0.5)0.5 (0.2--0.9)0.311 Platelet counts (× 10^9^/L)125.0--350.0186.0 (141.0--262.0)181.0 (148.5--237.5)191.0 (130.0--284.8)0.71 Haemoglobin \[g/L, mean (SD)\]130--175113.7 (26.0)131.5 (17.4)105.6 (25.4)\< 0.001 Hematocrit (%)40.0--50.033.8 (28.6--37.9)37.3 (34.9--40.4)30.8 (25.6--36.0)\< 0.001**Coagulation function** Prothrombin time (s)10.5--13.513.0 (11.9--14.1)13.4 (12.3--13.9)12.9 (11.8--14.5)0.665 Activated partial thromboplastin time (s)21.0--37.033.9 (29.1--40.4)34.7 (32.5--40.2)32.1 (29.0--41.6)0.402 International normalized ratio0.8--1.31.1 (1.0--1.2)1.0 (0.9--1.1)1.1 (1.0--1.3)0.002 D-dimer (μg/L)0--1.53.1 (1.6--8.0)1.1 (0.7--2.8)4.4 (2.6--9.6)\< 0.001**Blood biochemistry** Albumin, median \[g/L, mean (IQR)\]40.0--55.030.1 (25.6--33.7)34.6 (31.3--36.5)26.8 (24.2--31.6)\< 0.001 Alanine aminotransferase(U/L)9.0--50.038.0 (27.8--60.1)33.5 (22.0--54.3)43.0 (28.8--70.0)0.241 Aspartate aminotransferase (U/L)15.0--40.048.4 (31.8--91.3)47.0 (32.6--69.5)48.5 (29.3--100.8)0.567 Total bilirubin (μmol/L)0.21.015.7 (10.7--22.2)20.7 (12.8--27.6)15.4 (8.6--21.0)0.025 Serum creatinine (μmol/L)57.0--111.077.0 (50.2--124.4)75.1 (56.3--92.7)77.0 (48.3--155.1)0.727 Blood urea nitrogen (mmol/L)3.6--9.57.1 (5.4--9.6)6.6 (5.5--8.3)7.4 (5.3--12.8)0.151 Creatine kinase MB form (U/L)0--5.02.0 (1.1--5.0)0.8 (0.4--1.9)2.8 (2.0--7.6)\< 0.001 NT-pro BNP (pg/ml)0--125.01778.5 (223.8--6170.5)133.5 (71.8--772.0)3298.5 (473.8--7077.5)\< 0.001 Lactate dehydrogenase (U/L)120.0--350.0749.0 (427.0--1290.0)693.0 (399.0--883.5)936.5 (490.8--1535.5)0.089**Arterial blood gas** Sodium (mmol/L)135.0--145.0136.0 (132.0--141.0)135.2 (132.5--141.6)136.0 (131.8--141.0)0.797 Potassium (mmol/L)3.5--5.03.6 (3.4--4.1)3.5 (3.2--3.6)3.8 (3.5--4.3)0.02 Chloride (mmol/L)90.0--110.0101.0 (97.8--106.0)101.0 (98.0--106.5)101.0 (96.8--105.3)0.695 PaO~2~ (mmHg)83.0--108.081.0 (61.4--99.6)65.3 (57.5--82.0)86.5 (64.6--130.0)0.02 PaCO~2~ (mmHg)35.0--48.033.6 (30.7--40.6)33.3 (31.4--36.6)34.0 (28.8--44.9)0.72 PaO~2~:FIO~2~ (mmHg)400.0--500.0162.2 (119.4--219.3)132.9 (116.2--174.9)181.3 (119.0--279.9)0.07 Glucose (mmol/L)3.9--6.19.2 (6.8--13.8)11.1 (8.3--14.9)8.8 (5.9--13.0)0.155 Lactate (mmol/L)0.5--1.62.1 (1.5--2.9)2.5 (1.6--3.0)2.0 (1.5--2.6)0.226**Immune-related biomarkers** Absolute T lymphocyte counts (count/μl)NA440.0 (329.5--581.0)329.5 (313.3--472.3)492.0 (382.0--720.0)0.004 Absolute helper T lymphocyte counts (count/μl)NA246.0 (188.0--372.0)201.0 (156.0--264.5)308.0 (208.0--420.0)0.034 Absolute cytotoxic T lymphocyte counts (count/μl)NA152.0 (102.0--236.0)101.0 (91.0--153.8)180.0 (132.0--264.0)0.003 CD4/CD8 ratio \[mean (SD)\]0.9--3.61.8 (0.9)1.9 (0.9)1.8 (0.9)0.709**Inflammation-related biomarkers** C-reactive protein (mg/L)0--10.0104.7 (30.9--148.4)119.2 (70.7--154.6)37.2 (23.8--111.6)0.008 Procalcitonin (ng/ml)0--5.00.5 (0.2--3.8)0.2 (0.2--0.3)1.4 (0.3--5.5)\< 0.001Data were median (IQR) if not otherwise specified. n (%) referred to the total number of patients with available data. *P* values indicated differences between SARS-CoV-2-induced sepsis and bacteria-induced sepsis, in which *P* \< 0.05 was deemed as statistical significance*SD* Standard deviation, *BNP* Brain natriuretic peptide, *NA* Not applicable

In this study, ICU patients with SARS-CoV-2-induced sepsis and those with bacterial sepsis revealed comparable demographic characteristics, like age, gender distribution, and comorbidities, after rigorous screening processes. However, patients with bacterial sepsis were found with more severe organ dysfunction and poor outcomes when compared with those caused by SARS-CoV-2-induced sepsis, including higher values in SOFA and APACHE II, as well as more ICU deaths. The different patterns of immune responses might be the major cause of the divergent outcomes between viral and bacterial sepsis. We further found that failed homeostasis was characterized in both bacterial and viral sepsis but triggered by different pathogens. In the development of viral sepsis, the loss of T lymphocytes and their subsets was the dominant characteristics of dysregulated immune response, thereby contributing to the imbalance between innate and adaptive immune systems; while excessive inflammatory activation was the main feature of bacterial sepsis, which further resulted in intractable immune suppression and multiple organ dysfunction. This is the first report that compared clinical features and host responses between bacterial and SARS-CoV-2-induced viral sepsis. These findings might not only suggest divergent host responses to bacteria and virus but also provide novel insights into further researches on the development of sepsis with underlying etiology of various pathogens.
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**Additional file 1.** Appendix Table 1. Baseline characteristics of critically ill patients with SARS-CoV-2- and bacteria-induced sepsis.
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**Additional file 2.** Appendix Figure 1. Flow diagram of patient inclusion. COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SOFA: Sequential organ failure assessment; ICU: Intensive care unit; LOS: Length of stay; CAP: Community-acquired pneumonia.
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